Stallergenes Greer : Feedback Road show : reconstruction active
>Levier S1 - Rappelons que le CA S1 était en hausse de 10% et l’EBITDA est passé de 8 M€ à 27,6 M€.La bonne performance du S1 révèle en réalité un contraste entre VSC et VSL, à l’intérieur de la VSL, des disparités entre marchés vétérinaire aux USA (-14%), baisse optique de la PdM sur le comprimé aux USA (-4 pts), une bonne captation de nouveaux prescripteurs aux USA (bulk / >+15%e lfl.), et un vif regain de PdM de Staloral© (hausse des traitements initiaux en E...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.